Steven A. Kaplan
Weill Medical College of Cornell University
New York-Presbyterian Hospital/Weill Cornell Medical Center
USA
Name/email consistency: high
- Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Kaplan, S.A., He, W., Koltun, W.D., Cummings, J., Schneider, T., Fakhoury, A. Eur. Urol. (2013)
- Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. Kaplan, S.A., Roehrborn, C.G., Gong, J., Sun, F., Guan, Z. BJU Int. (2012)
- Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Kaplan, S.A., Roehrborn, C.G., Abrams, P., Chapple, C.R., Bavendam, T., Guan, Z. Int. J. Clin. Pract. (2011)
- Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. Kaplan, S.A., Lee, J.Y., Meehan, A.G., Kusek, J.W. J. Urol. (2011)
- Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone. Kaplan, S.A., Lin, J., Johnson-Levonas, A.O., Shah, A.K., Meehan, A.G. Aging. Male (2010)
- Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Kaplan, S.A., Johnson-Levonas, A.O., Lin, J., Shah, A.K., Meehan, A.G. Aging. Male (2010)
- Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Kaplan, S.A., Goldfischer, E.R., Steers, W.D., Gittelman, M., Andoh, M., Forero-Schwanhaeuser, S. Aging. Male (2010)
- PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Kaplan, S.A., Roehrborn, C.G., Meehan, A.G., Liu, K.S., Carides, A.D., Binkowitz, B.S., Heyden, N.L., Vaughan, E.D. Urology (2009)
- Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Kaplan, S.A., McCammon, K., Fincher, R., Fakhoury, A., He, W. J. Urol. (2009)
- Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. Kaplan, S.A., Roehrborn, C.G., Chapple, C.R., Rosen, R.C., Irwin, D.E., Kopp, Z., Aiyer, L.P., Mollon, P. BJU Int. (2009)
- Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. Kaplan, S.A., Roehrborn, C.G., McConnell, J.D., Meehan, A.G., Surynawanshi, S., Lee, J.Y., Rotonda, J., Kusek, J.W., Nyberg, L.M. J. Urol. (2008)
- Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. Kaplan, S.A., Walmsley, K., Te, A.E. J. Urol. (2008)
- Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Kaplan, S.A., Roehrborn, C.G., Chancellor, M., Carlsson, M., Bavendam, T., Guan, Z. BJU Int. (2008)
- Urinary retention and post-void residual urine in men: separating truth from tradition. Kaplan, S.A., Wein, A.J., Staskin, D.R., Roehrborn, C.G., Steers, W.D. J. Urol. (2008)
- Introduction: BPH and sexual dysfunction--recommendations for the primary care physician and urologist. Kaplan, S.A. Int. J. Impot. Res. (2008)
- Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. Kaplan, S.A. BJU Int. (2008)
- Identification of the patient with enlarged prostate: diagnosis and guidelines for management. Kaplan, S.A. Osteopath. Med. Prim. Care (2007)
- Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Kaplan, S.A., Gonzalez, R.R., Te, A.E. Eur. Urol. (2007)
- Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Kaplan, S.A., Hatzichristou, D. Eur. Urol. (2007)
- Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. Kaplan, S.A., DE Rose, A.F., Kirby, R.S., O'leary, M.P., McVary, K.T. BJU Int. (2006)
- Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Kaplan, S.A., Roehrborn, C.G., Dmochowski, R., Rovner, E.S., Wang, J.T., Guan, Z. Urology (2006)
- Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey. Kaplan, S., Naslund, M. Int. J. Clin. Pract. (2006)
- The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. Kaplan, S.A., Meehan, A.G., Shah, A. J. Urol. (2006)
- Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Kaplan, S.A., Roehrborn, C.G., Rovner, E.S., Carlsson, M., Bavendam, T., Guan, Z. JAMA (2006)
- Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. Kaplan, S.A., Walmsley, K., Te, A.E. J. Urol. (2005)
